

PRESS RELEASE

Noida, Tuesday, August 11, 2015

JUBILANT LIFE SCIENCES – Q1 FY 2016 RESULTS

The Board of Jubilant Life Sciences Limited, an integrated global pharmaceuticals and life sciences company met today to approve financial results for the quarter ended June 30, 2015.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:

“Q1'16 results are, in many ways, a reflection of initiatives undertaken over the last few quarters. Our Pharmaceuticals segment has delivered strong results led by sustained performance in Radiopharmaceuticals and API business. We are looking forward to improved performance in our CMO business, post successful completion of the inspection status during the quarter. In Life Science Ingredients, we witnessed better margins across most businesses during the quarter. With some of the business related concerns now behind us, we believe that our performance is back on track and expect to continue the momentum going forward.”

Q1 FY16 Highlights

- Consolidated revenue at Rs. 1,459 Crore
 - Pharmaceuticals revenue at Rs. 741 Crore, contributing 51% to the overall mix
 - LSI revenue at Rs. 718 Crore, contributing 49% to the overall mix
 - International revenues at Rs. 1,056 Crore, contributing 72% to the overall mix
- EBITDA at Rs. 333 Crore, growing 123% YoY with EBITDA margins at 22.8%
- PAT at Rs. 128 Crore, with an EPS of Rs. 8.04 in the quarter

Pharmaceuticals Segment Review

In Q1 FY2016, Income from Operations of the Pharmaceuticals segment was at Rs. 741 Crore, contributing 51% to the revenue mix. The segment EBITDA stood at Rs. 225 Crore, with EBITDA margins at 30.4%. Key developed markets share was 87% of total Pharmaceutical segment revenues. Revenues from North America increased 35% YoY to Rs 569 Crore during the quarter. India business grew 41% YoY while ROW business grew 26% YoY.



Life Science Ingredients Segment Review

In Q1 FY2016, Income from Operations of the Life Science Ingredients segment stood at Rs. 718 Crore, contributing 49% to the revenue mix. The segment EBITDA stood at Rs 121 Crore, with EBITDA margins at 16.9%. International markets contributed 49% to the total LSI revenues with key developed markets share at 32% of the total sales in the segment.

Geographical Overview

In Q1 FY2016, revenues from North America stood at Rs. 619 crore, contributing 42% to the overall revenues. Revenues from Europe and Japan stood at Rs. 254 crore, contributing 17% to the revenue mix. Domestic revenues stood at Rs. 402 crore, thus contributing 28% to the overall mix. Revenues in ROW including China was at Rs. 184 crore, thus contributing 13% to the overall mix.

Outlook

In FY2016, revenue growth is expected to be driven by Pharmaceuticals segment primarily led by growth in Radiopharmaceuticals, normalization of CMO business and growth in generics business through new products. Our Life Science Ingredients segment is expected to deliver better results compared to FY2015 led by improved operational efficiency and growth in Nutritional Products and Specialty Ingredients.

About Jubilant Life Sciences

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceuticals and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6000 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com



For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Sudhakar Safaya
Jubilant Life Sciences Limited
Ph: +91-120 436 1034
E-mail: sudhakar_safaya@jubl.com

Saurabh Gupta
Perfect Relations
Ph: +91 9818075578
E-mail: sgupta@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.